Chemotherapy versus chemotherapy plus immune checkpoint inhibitors for the first‐line treatment of unresectable thymic carcinoma: A multicenter retrospective study

Documenti analoghi

• Cardiovascular adverse events associated with immune checkpoint inhibitors: A retrospective multicenter cohort study
  di: Yi Zheng, et al.
  Pubblicazione: (2024)
• A dramatic response to an immune checkpoint inhibitor plus chemotherapy in a patient with metastatic metaplastic carcinoma of the breast: A case report
  di: Yumiko Koi, et al.
  Pubblicazione: (2024)
• Comparative efficacy of immune checkpoint inhibitors versus chemotherapy alone in diffuse pleural mesothelioma
  di: Xuemei Zhang, et al.
  Pubblicazione: (2024)
• Cabozantinib with immune checkpoint inhibitor versus cabozantinib monotherapy in patients with metastatic clear cell renal cell carcinoma progressing after prior immune checkpoint inhibitor
  di: Georges Gebrael, et al.
  Pubblicazione: (2024)
• Efficacy and safety of novel immune checkpoint inhibitor‐based combinations versus chemotherapy as first‐line treatment for patients with extensive‐stage small cell lung cancer: A network meta‐analysis
  di: Chuang Yang, et al.
  Pubblicazione: (2024)